Key result
De novo fibrate use linked to ~7% lower major cardiovascular events risk vs. statins in incident CKD.
Why the study?
Atherogenic lipid profiles with hypertriglyceridemia and impaired HDL-C metabolism contribute to adverse CVD outcomes in CKD, but evidence on the CVD outcomes of triglyceride-targeting lipid-lowering therapies such as fibrates and niacin remains limited.
Does de novo fibrate or niacin therapy reduce major adverse cardiovascular events compared to statin therapy in patients with incident chronic kidney disease?
Cohort (n=46,904)
Yes
Does de novo fibrate or niacin therapy reduce major adverse cardiovascular events compared to statin therapy in patients with incident chronic kidney disease?
In a large cohort of US Veterans with incident CKD, initiating fibrates was associated with a modestly lower risk of MACE compared to initiating statins, whereas niacin showed no significant difference, highlighting the need for dedicated RCTs in this population.
Answers are grounded in this paper and cite their sources.
May inform lipid therapy choices in CKD but should not change practice; leaves open optimal MACE prevention strategy versus statins.
Background In patients with chronic kidney disease (CKD), atherogenic lipid profiles, characterized by hypertriglyceridemia and impaired high-density lipoprotein cholesterol (HDL-C) metabolism, contribute to adverse cardiovascular disease (CVD) outcomes. Since evidence on the CVD outcomes of triglyceride (TG)-targeting lipid-lowering therapies (LLTs), such as fibrates and niacin, remains limited, kidney disease guidelines recommend further investigation. Methods We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US Veterans with normal kidney function enrolled between October 2004 and September 2006. We identified 46,904 incident CKD patients initiating de novo fibrate (n=2,495), niacin (n=1,362), or statin (n=43,047) therapy using prescription data. We used multivariable adjusted Cox proportional hazards models to compare the associations of fibrate and niacin vs. statin use with major adverse cardiovascular events [MACE] (composite of acute myocardial infarction, ischemic stroke, congestive heart failure, or all-cause death) during follow-up of up to 10 years. Results Of the 46,904 patients in the analytical cohort, 16,191 (event rate, 79.2 [95% CI: 78.0, 80.4] per 1000 person years) experienced MACE after a median follow-up of 3.70 years. The risk of MACE was 7% lower and significantly different (Hazard Ratio [HR], 0.93 [95% CI, 0.86, 0.99]; p=0.03) in de novo fibrate users compared to statin users. Niacin users, however, did not experience a significant difference in MACE risk, compared with statin initiators (Table). Conclusion In this large nationwide cohort of patients with CKD, de novo fibrate use was associated with a lower risk of MACE than de novo statin use. Niacin use, on the other hand, was not associated with a significantly different risk compared to statin use. Randomized controlled trials are needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Naim et al. (2026) conducted a cohort in Incident chronic kidney disease (CKD) (n=46,904). De novo fibrate (n=2,495) or niacin (n=1,362) therapy vs. De novo statin therapy (n=43,047) was evaluated on Major adverse cardiovascular events (MACE), defined as a composite of acute myocardial infarction, ischemic stroke, congestive heart failure, or all-cause death (HR 0.93, 95% CI 0.86-0.99, p=0.03). De novo fibrate use was associated with a 7% lower risk of major cardiovascular events compared to statin use in patients with incident CKD.
Synapse has enriched 10 related papers. Consider them for comparative context: